O'Melveny Reps Chinese Co. In $118M Complete Genomics Deal

Law360, New York (September 17, 2012, 5:28 PM EDT) -- Gene sequencing company Complete Genomics Inc. has agreed to let a U.S. subsidiary of Chinese rival BGI-Shenzhen snap it up in a merger deal worth about $117.6 million, the companies announced Monday.

Complete shareholders will receive $3.15 per share in the deal, a 54 percent premium over the $2.04 Complete stock closed at on June 4, the last day of trading before a previous temporary trading halt following a significant share price slide. The troubled Mountain View, Calif.-based company had said the halt would let it...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.